{"id":"2388915e9482","type":"article","url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","title":"POST-PCI: routine functionele testen versus standaardzorg na PCI bij hoog risico","title_en":"Routine Functional Testing or Standard Care in High-Risk Patients after PCI.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2208335","source_url":"https://doi.org/10.1056/NEJMoa2208335","authors":["Duk-Woo Park","Do-Yoon Kang","Jung-Min Ahn","Sung-Cheol Yun","Yong-Hoon Yoon","Seung-Ho Hur","Cheol Hyun Lee","Won-Jang Kim","Se Hun Kang","Chul Soo Park","Bong-Ki Lee","Jung-Won Suh","Jung Han Yoon","Jae Woong Choi","Kee-Sik Kim","Si Wan Choi","Su Nam Lee","Seung-Jung Park"],"significance":8,"published":"2022-09-08","source_date":"2022-09-08","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"The POST-PCI trial demonstrated that routine functional testing after PCI in high-risk patients did not improve clinical outcomes compared with standard care at 2 years. The results argued against routine surveillance testing as a post-PCI follow-up strategy.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De POST-PCI-trial in de NEJM toonde dat routinematige functionele testen na PCI bij hoogrisicopatiënten niet leidde tot betere klinische uitkomsten vergeleken met standaardzorg. Dit pleit tegen routinematige stresstesten in de follow-up na succesvolle PCI.","abstract_original":"BACKGROUND: There are limited data from randomized trials to guide a specific follow-up surveillance approach after myocardial revascularization. Whether a follow-up strategy that includes routine functional testing improves clinical outcomes among high-risk patients who have undergone percutaneous coronary intervention (PCI) is uncertain. METHODS: We randomly assigned 1706 patients with high-risk anatomical or clinical characteristics who had undergone PCI to a follow-up strategy of routine functional testing (nuclear stress testing, exercise electrocardiography, or stress echocardiography) at 1 year after PCI or to standard care alone. The primary outcome was a composite of death from any cause, myocardial infarction, or hospitalization for unstable angina at 2 years. Key secondary outcomes included invasive coronary angiography and repeat revascularization. RESULTS: The mean age of the patients was 64.7 years, 21.0% had left main disease, 43.5% had bifurcation disease, 69.8% had multivessel disease, 70.1% had diffuse long lesions, 38.7% had diabetes, and 96.4% had been treated with drug-eluting stents. At 2 years, a primary-outcome event had occurred in 46 of 849 patients (Kaplan-Meier estimate, 5.5%) in the functional-testing group and in 51 of 857 (Kaplan-Meier estimate, 6.0%) in the standard-care group (hazard ratio, 0.90; 95% confidence interval [CI], 0.61 to 1.35; P = 0.62). There were no between-group differences with respect to the components of the primary outcome. At 2 years, 12.3% of the patients in the functional-testing group and 9.3% in the standard-care group had undergone invasive coronary angiography (difference, 2.99 percentage points; 95% CI, -0.01 to 5.99), and 8.1% and 5.8% of patients, respectively, had undergone repeat revascularization (difference, 2.23 percentage points; 95% CI, -0.22 to 4.68). CONCLUSIONS: Among high-risk patients who had undergone PCI, a follow-up strategy of routine functional testing, as compared with standard care alone, did not improve clinical outcomes at 2 years. (Funded by the CardioVascular Research Foundation and Daewoong Pharmaceutical; POST-PCI ClinicalTrials.gov number, NCT03217877.)."}